HYLEUKIN Trademark

Trademark Overview


On Thursday, November 23, 2017, a trademark application was filed for HYLEUKIN with the United States Patent and Trademark Office. The USPTO has given the HYLEUKIN trademark a serial number of 87696005. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, July 13, 2020. This trademark is owned by Genexine, Inc.. The HYLEUKIN trademark is filed in the Pharmaceutical Products category with the following description:

Antibiotics; Anti-cancer preparations; Anti-inflammatory preparations, namely, anti-inflammatory gels, ointments, salves, sprays, creams, pills, powders, granules, tablets, capsules, depots, suppository, syrup, tinctures and emulsion; Antiviral agent against human papilloma virus; Blood solvent, namely, blood plasma, albumin, globulin, fibrinogen, thrombocyte and platelets; Cardiovascular pharmaceutical preparations for the treatment and prevention of heart and vascular diseases; Dermatological pharmaceutical products; DNA vaccines; Drugs for medical purposes, namely, pharmaceutical drug preparations for the treatment and prevention of human papilloma virus infectious disease, cancer and cervical intraepithelial neoplasia; Injectable pharmaceuticals for medical purposes, namely, for the treatment and prevention of human papilloma virus infectious disease, cancer and cervical intraepithelial neoplasia; Medicines for sensory organs, namely, pharmaceutical preparations for the prevention,...
hyleukin

General Information


Serial Number87696005
Word MarkHYLEUKIN
Filing DateThursday, November 23, 2017
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, July 13, 2020
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, April 17, 2018

Trademark Statements


Goods and ServicesAntibiotics; Anti-cancer preparations; Anti-inflammatory preparations, namely, anti-inflammatory gels, ointments, salves, sprays, creams, pills, powders, granules, tablets, capsules, depots, suppository, syrup, tinctures and emulsion; Antiviral agent against human papilloma virus; Blood solvent, namely, blood plasma, albumin, globulin, fibrinogen, thrombocyte and platelets; Cardiovascular pharmaceutical preparations for the treatment and prevention of heart and vascular diseases; Dermatological pharmaceutical products; DNA vaccines; Drugs for medical purposes, namely, pharmaceutical drug preparations for the treatment and prevention of human papilloma virus infectious disease, cancer and cervical intraepithelial neoplasia; Injectable pharmaceuticals for medical purposes, namely, for the treatment and prevention of human papilloma virus infectious disease, cancer and cervical intraepithelial neoplasia; Medicines for sensory organs, namely, pharmaceutical preparations for the prevention, treatment, and cure of diseases and conditions impacting the eyes, ears, nose, mouth and nervous system; Pharmaceutical agents affecting digestive organs; Pharmaceutical agents affecting metabolism; Pharmaceutical preparations and compositions for the treatment and prevention of cancer; Pharmaceutical preparations for activating cellular function; Pharmaceutical preparations for anticancer immunotherapy; Pharmaceutical preparations for digestive organs, namely, for the prevention, treatment, and cure of diseases and conditions impacting digestive organs; Pharmaceutical preparations for gene therapy; Pharmaceutical preparations for immunomodulatory purposes, namely, for the regulation of immune functions; Pharmaceutical preparations for immunotherapy; Pharmaceutical preparations for preventing and treating obese; Pharmaceutical preparations for regulating the immune system; Pharmaceutical preparations for the prevention of osteoporosis; Pharmaceutical preparations for the treatment of autoimmune diseases; Pharmaceutical preparations for the treatment of cardiovascular disease; Pharmaceutical preparations for the treatment of cervical cancer; Pharmaceutical preparations for the treatment of cervical intraepithelial neoplasia; Pharmaceutical preparations for the treatment of cervical pre-cancer; Pharmaceutical preparations for the treatment of eye diseases and conditions; Pharmaceutical preparations for the treatment of head and neck cancer; Pharmaceutical preparations for the treatment of hormonal disorders; Pharmaceutical preparations for the treatment of multiple sclerosis; Pharmaceutical preparations for the treatment of osteoporosis; Pharmaceutical preparations for treating diabetes; Pharmaceutical preparations for treating hypertension; Pharmaceutical preparations for treating malignant tumours; Pharmaceutical preparations for urogenital organs; Pharmaceutical preparations for wounds; Pharmaceutical products and preparations, namely, for the treatment and prevention of human papilloma virus infectious disease, cancer and cervical intraepithelial neoplasia; Pharmaceutical products for the treatment of bone diseases; Pharmaceutical products for the treatment of cancer; Pharmaceutical products for the treatment of infectious diseases; Pharmaceutical products for the treatment of viral and infectious diseases; Pharmaceutical products for the treatment of viral diseases; Preventive vaccines; Preventive vaccines against human papilloma virus infections; Therapeutic vaccines; and Vaccines

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, December 5, 2017
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameGenexine, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressSeongnamsi, Gyeonggido
KR

Party NameGenexine, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressSeongnamsi, Gyeonggido
KR

Trademark Events


Event DateEvent Description
Monday, July 13, 2020ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, July 13, 2020ABANDONMENT - NO USE STATEMENT FILED
Wednesday, December 4, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, December 2, 2019EXTENSION 3 GRANTED
Monday, December 2, 2019EXTENSION 3 FILED
Monday, December 2, 2019TEAS EXTENSION RECEIVED
Saturday, June 8, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, June 6, 2019EXTENSION 2 GRANTED
Thursday, June 6, 2019EXTENSION 2 FILED
Thursday, June 6, 2019TEAS EXTENSION RECEIVED
Thursday, December 13, 2018NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, December 11, 2018EXTENSION 1 GRANTED
Tuesday, December 11, 2018EXTENSION 1 FILED
Tuesday, December 11, 2018TEAS EXTENSION RECEIVED
Tuesday, June 12, 2018NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, April 17, 2018OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, April 17, 2018PUBLISHED FOR OPPOSITION
Wednesday, March 28, 2018NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Friday, March 9, 2018APPROVED FOR PUB - PRINCIPAL REGISTER
Thursday, March 8, 2018ASSIGNED TO EXAMINER
Tuesday, December 5, 2017NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Monday, November 27, 2017NEW APPLICATION ENTERED IN TRAM